Study challenges the use of biochemical recurrence as prosta

A UCLA-led study found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient's long-term overall survival.

Related Keywords

Amar Kishan , Soumyajit Roy , Danielle Ellis , Tahmineh Romero , Health Jonsson Comprehensive Cancer Center , David Geffen School Of Medicine , Rush University Medical Center , David Geffen School , Jonsson Comprehensive Cancer Center , Rush University Medical , Cancer , Prostate , Prostate Cancer , Androgen , Androgen Deprivation Therapy , Ntigen , Ncology , Prostate Specific Antigen , Radiation Therapy , Radiotherapy ,